A Phase IIA Study of MK0457 in Patients With Cancer of the Lung (0457-006)

Merck Sharp & Dohme (MSD)

Status and phase: Terminated; Phase 2

Conditions: Carcinoma, Non-Small-Cell Lung

Treatments: Drug: MK0457

Study type: Interventional

Funder types: Industry

Identifiers

NCT00290550

2006_008

0457-006

Details and patient eligibility

About

This is a study to evaluate the effectiveness of an investigational drug in patients with cancer of the lung.

Enrollment: 22 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who are at least 18 years of age with cancer of the lung and who have had either no previous treatment or 1 previous treatment for advanced cancer of the lung. Certain other treatments may also be allowed (prior cytotoxic chemotherapy in the adjuvant setting)

Exclusion criteria

• Patients who have had treatment with any investigational therapy within the past 30 days are not eligible.
• Patients who have had a disease or medical condition that is not controlled will not be eligible.
• Patients who are pregnant or breastfeeding are not eligible.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

22 participants in 1 patient group

1

Other group

Description:

MK-0457

Treatment:

Drug: MK0457